{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-24-000124","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.628420+00:00","generated_at":"2026-06-02T16:29:46.069073+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Globus Medical Q1 net sales $606.7M (+119% YoY); raises FY2024 guidance","bullets":["Net sales $606.7M, up 119.3% YoY, driven by NuVasive addition and higher spine/enabling tech volumes.","GAAP net loss $7.1M (($0.05) diluted EPS); non-GAAP diluted EPS $0.72, up 36.4% from $0.53.","Non-GAAP adjusted EBITDA $166.6M, or 27.5% of net sales.","FY2024 revenue guidance raised to $2.460-2.485B; non-GAAP EPS guidance raised to $2.75-2.85.","Integration of NuVasive progressing; management cites strong surgeon and sales force retention."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-24-000124","json":"https://secwatch.observer/filing/0001562762-24-000124.json","markdown":"https://secwatch.observer/filing/0001562762-24-000124.md","text":"https://secwatch.observer/filing/0001562762-24-000124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000124/0001562762-24-000124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000124/gmed-20240507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:29:46.069073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"089a01d99577bf0137391810ad5aa4f27062ade9","claim":"GLOBUS MEDICAL INC reported three-month period ended March 31, 2024 results: revenue $606.7 million, net income $7.1 million net loss, EPS ($0.05).","evidence_excerpt":"Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 3 1 , 202 4 .  · Worldwide net sales were $ 606.7 million , an increase of 119 . 3 % , or 119.8% on a constant currency basis · GAAP net loss for the quarter was $ 7. 1 million · GAAP d iluted e arnings p er share (“ EPS ”) was ( $0. 0","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000124/0001562762-24-000124-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three-month period ended March 31, 2024"},{"label":"Revenue","value":"$606.7 million"},{"label":"Net income","value":"$7.1 million net loss"},{"label":"EPS","value":"($0.05)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}